Merck KGaA has agreed to acquire Bio-Techne in an all-cash transaction valued at $11.3 billion, the companies announced. The German conglomerate aims to strengthen its presence in the life science tools market by adding Bio-Techne's multiomics offerings, analytical technologies, and integrated workflow solutions.
The deal brings together Merck's existing platforms in research, bioprocessing, and advanced therapeutics with Bio-Techne's specialized capabilities. The combined entity is positioned to support customers across the full spectrum from discovery and translational research through development, testing, and commercial manufacturing.
The acquisition is expected to close in the first half of 2025, subject to regulatory approvals and customary closing conditions. Bio-Techne shareholders will receive $78.60 per share in cash, representing a premium over the stock's recent trading price.
For Merck, the purchase marks a significant expansion in its life science division, which already generates substantial revenue. Bio-Techne, a Minnesota-based company with expertise in proteins, antibodies, and assays, posted revenue of approximately $1.1 billion in its most recent fiscal year.
Some analysts have questioned whether the premium paid fully reflects integration risks and the cyclical nature of research spending, which could impact near-term returns. The deal underscores ongoing consolidation in the life science tools sector as companies seek to offer end-to-end solutions to pharmaceutical and biotech customers.